The pooled multivariate hazard ratios for GTR (HR = 0.70, 95% CI: 0.53–0.93) and methylated MGMT promoter status (HR = 0.45, 95% CI: 0.27–0.76) highlight their critical roles in the management of recurrent glioblastoma. Here, MGMT is linked to glioblastoma.